AstraZeneca
Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer
The firm hopes its qPCR-based liquid biopsy test could help identify early-stage NSCLC patients eligible for adjuvant or neoadjuvant anti-EGFR TKI treatment.
AstraZeneca's Lynparza Fails Phase II, Single-Arm Study in IDH-Mutant High-Grade Glioma
The trial did not meet its prespecified six-month progression-free survival rate, with only 11 of 35 patients reaching six months without progression.
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
Akoya Biosciences, AstraZeneca Collaborate on Spatial Biomarker Profiling for Immuno-Oncology
The firms will study drug mechanisms of action, confirm the prevalence of targets, and discover predictive signatures for subsequent trial designs.
Clovis' Rubraca Benefits BRCA1/2, PALB2-Mutated Pancreatic Cancer Patients as Maintenance Therapy
Premium
The study explored whether the PARP inhibitor benefitted patients with a wider range of mutations and pancreatic cancer subtypes than approved drugs.